https://thebostonexaminer.com/article/914366982-nsg-norel-names-new-chief-executive-officer The Boston Examiner en PressRelease 2026-05-22T16:19:06+00:00 NSG-NOREL Names New Chief Executive Officer https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24864689-nsg-norel-1332x205.png https://thebostonexaminer.com/article/914310504-united-planet-launches-taste-of-unity-global-cookbook-to-celebrate-cross-cultural-connection The Boston Examiner en PressRelease 2026-05-22T13:00:00+00:00 United Planet Launches Taste of Unity Global Cookbook to Celebrate Cross Cultural Connection https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24864468-cookbook-1-624x351.jpeg https://thebostonexaminer.com/article/914247960-nurl-health-launches-wearable-to-detect-veteran-relapse-before-it-happens The Boston Examiner en PressRelease 2026-05-22T10:15:04+00:00 NURL Health Launches Wearable to Detect Veteran Relapse Before It Happens https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24864254-nurl-band-1175x952.jpeg https://thebostonexaminer.com/article/914401160-tigr-alert-up-fintech-holding-investigated-for-possible-securities-fraud-investors-who-have-lost-money-should-contact-block-leviton-to-recover The Boston Examiner en PressRelease 2026-05-22T17:05:50+00:00 $TIGR ALERT: UP Fintech Holding Investigated for Possible Securities Fraud; Investors Who Have Lost Money Should Contact Block & Leviton to Recover Losses https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://thebostonexaminer.com/article/914384377-futu-holdings-ltd-shares-plummet-over-30-investors-should-contact-block-leviton-to-find-out-how-they-might-recover-losses-through-the-firm-s The Boston Examiner en PressRelease 2026-05-22T16:12:31+00:00 Futu Holdings Ltd. Shares Plummet Over 30%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Losses Through The Firm’s Investigation https://ml.globenewswire.com/media/582f8ff5-dda1-458c-b0b6-cc833c566289/small/block-leviton-llp-logo.jpg https://thebostonexaminer.com/article/914375613-die-liquidstack-gigamodular-cdu-plattform-ist-nun-mit-einer-auf-14-mw-erweiterten-kapazit-t-auf-dem-markt-erh-ltlich The Boston Examiner en PressRelease 2026-05-22T15:01:40+00:00 Die LiquidStack GigaModular™ CDU-Plattform ist nun mit einer auf 14 MW erweiterten Kapazität auf dem Markt erhältlich https://ml.globenewswire.com/media/f7d81e8c-8577-4551-b882-3ddc1a8387be/small/lqs-logo-horizontal-yellowblack-0821-png.png https://thebostonexaminer.com/article/914375616-la-plateforme-cdu-gigamodular-de-liquidstack-est-d-sormais-disponible-la-vente-avec-une-capacit-tendue-14-mw The Boston Examiner en PressRelease 2026-05-22T15:01:40+00:00 La plateforme CDU GigaModular™ de LiquidStack est désormais disponible à la vente avec une capacité étendue à 14 MW https://ml.globenewswire.com/media/f7d81e8c-8577-4551-b882-3ddc1a8387be/small/lqs-logo-horizontal-yellowblack-0821-png.png https://thebostonexaminer.com/article/914367966-foundation-announces-6-4m-round-and-availability-of-passport-prime-the-first-human-authority-hardware-device The Boston Examiner en PressRelease 2026-05-22T14:48:26+00:00 Foundation Announces $6.4M Round and Availability of Passport Prime, the First Human Authority Hardware Device https://ml.globenewswire.com/media/5c7ed737-8583-47d6-b6f9-44116cd022c0/medium/foundation-announces-6-4m-round-and-availability-of-passport.jpg https://thebostonexaminer.com/article/914367936-sophos-named-a-champion-in-omdia-cybersecurity-msp-ecosystems-leadership-matrix-2026 The Boston Examiner en PressRelease 2026-05-22T14:46:25+00:00 Sophos Named a Champion in Omdia Cybersecurity MSP Ecosystems Leadership Matrix 2026 https://ml.globenewswire.com/media/7a7cb431-cd32-404d-bdc0-6f6ea4fbcaf2/medium/omdia-cybersecurity-msp-ecosystems-leadership-matrix-2026.jpg https://thebostonexaminer.com/article/914359201-energy-and-sustainability-industry-sees-20-billion-in-investment-activity-as-grid-modernization-and-renewable-integration-drive-transformation The Boston Examiner en PressRelease 2026-05-22T13:32:18+00:00 Energy and Sustainability Industry Sees $20+ Billion in Investment Activity as Grid Modernization and Renewable Integration Drive Transformation https://ml.globenewswire.com/media/d0c282b6-d496-45a8-a941-33fa5c3e824c/small/bcc-logo-1200-630-png.png https://thebostonexaminer.com/article/914350177-agios-pyrukynd-mitapivat-approved-in-the-european-union-for-adults-with-thalassemia The Boston Examiner en PressRelease 2026-05-22T13:15:00+00:00 Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png https://thebostonexaminer.com/article/914331661-black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-conference The Boston Examiner en PressRelease 2026-05-22T12:00:00+00:00 Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference https://ml.globenewswire.com/media/b8da4d92-789b-4f0a-a1e2-2739af370155/small/bdtxlogo-pantone3135c-png-png.png https://thebostonexaminer.com/article/914331684-repligen-corporation-to-present-at-william-blair-46th-annual-growth-stock-conference The Boston Examiner en PressRelease 2026-05-22T11:30:00+00:00 Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg https://thebostonexaminer.com/article/914322024-destination-xl-group-inc-to-review-unsolicited-tender-offer-from-zodiac-partners-ii The Boston Examiner en PressRelease 2026-05-22T11:00:00+00:00 Destination XL Group, Inc. to Review Unsolicited Tender Offer From Zodiac Partners II https://ml.globenewswire.com/media/6ecdc08b-a991-4864-bec7-55382a7936d8/small/dxl-b-t-2020-jpg.jpg https://thebostonexaminer.com/article/914121399-madhat-media-formalizes-equity-engineering-partnership-with-sapientswift-solutions-to-accelerate-global-ddarp-deployment The Boston Examiner en PressRelease 2026-05-21T20:31:42+00:00 MadHat Media Formalizes Equity Engineering Partnership with SapientSwift Solutions to Accelerate Global DDARP Deployment https://thebostonexaminer.com/article/914111622-madhat-media-engages-ricci-capital-partners-to-lead-series-a-capital-formation The Boston Examiner en PressRelease 2026-05-21T19:43:10+00:00 MadHat Media Engages Ricci Capital Partners to Lead Series A Capital Formation https://thebostonexaminer.com/article/914109764-ricci-capital-partners-leadership-joins-madhat-media-board-of-advisors The Boston Examiner en PressRelease 2026-05-21T19:43:09+00:00 Ricci Capital Partners Leadership Joins MadHat Media Board of Advisors https://thebostonexaminer.com/article/914163048-biogen-and-denali-therapeutics-provide-update-on-phase-2b-luma-study-of-biib122-dnl151-in-early-stage-parkinson-s-disease The Boston Examiner en PressRelease 2026-05-21T22:00:00+00:00 Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease https://ml.globenewswire.com/media/80f9c524-3da2-4583-a763-0dad931fa182/small/biogen-logo-standard-rgb-r-jpg.jpg https://thebostonexaminer.com/article/914162553-crescent-biopharma-announces-trial-in-progress-presentation-for-ascend-study-of-cr-001-a-pd-1-x-vegf-bispecific-antibody-at-upcoming-american The Boston Examiner en PressRelease 2026-05-21T21:30:00+00:00 Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting https://ml.globenewswire.com/media/57dabf2a-90a3-4786-9c39-d1e71cc7707f/small/crescent-biopharma-logo-color-png.png https://thebostonexaminer.com/article/914162947-aktis-oncology-reports-first-in-human-clinical-imaging-and-dosimetry-data-for-aky-2519-demonstrating-robust-tumor-uptake-and-limited-normal-tissue The Boston Examiner en PressRelease 2026-05-21T21:21:08+00:00 Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors https://ml.globenewswire.com/media/490bbb9a-2b27-4a72-8d7a-333387326d8b/small/aktis-rgb-png.png https://thebostonexaminer.com/article/914162747-black-diamond-therapeutics-announces-positive-phase-2-results-for-silevertinib-in-frontline-nsclc-patients-with-egfr-non-classical-mutations The Boston Examiner en PressRelease 2026-05-21T21:13:52+00:00 Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations https://ml.globenewswire.com/media/b8da4d92-789b-4f0a-a1e2-2739af370155/small/bdtxlogo-pantone3135c-png-png.png https://thebostonexaminer.com/article/914161874-akari-therapeutics-reports-breakthrough-preclinical-data-demonstrating-synergistic-activity-of-aktx-101-with-kras-inhibition-in-kras-mutated The Boston Examiner en PressRelease 2026-05-21T21:01:00+00:00 Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models https://ml.globenewswire.com/media/8d978f50-07a9-40a3-be69-45f51ccd94d9/small/akari-logo-1-jpg.jpg https://thebostonexaminer.com/article/914161079-compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in-patients-with-advanced-malignancies-treated-in-the-post-checkpoint The Boston Examiner en PressRelease 2026-05-21T21:00:00+00:00 Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://thebostonexaminer.com/article/914161304-ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated-three-year-overall-survival-and-deep-responses-driven-by-tgf-inhibition-in-1l-r-m The Boston Examiner en PressRelease 2026-05-21T21:00:00+00:00 Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC https://ml.globenewswire.com/media/fdf5e06f-0748-428a-8f90-b0a1c6f7bdf3/small/bicara-logo-struck-png.png https://thebostonexaminer.com/article/914161429-immuneering-reports-17-3-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus The Boston Examiner en PressRelease 2026-05-21T21:00:00+00:00 Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy https://ml.globenewswire.com/media/81d0c83f-ae53-4d6e-9c5e-d6963e02f29d/small/immuneering-logo-cropped-1-jpg.jpg https://thebostonexaminer.com/article/914161460-rgenta-therapeutics-presents-positive-preliminary-data-from-ongoing-phase-1a-b-clinical-trial-of-rgt-61159-in-patients-with-adenoid-cystic-carcinoma The Boston Examiner en PressRelease 2026-05-21T21:00:00+00:00 Rgenta Therapeutics Presents Positive Preliminary Data from Ongoing Phase 1a/b Clinical Trial of RGT-61159 in Patients with Adenoid Cystic Carcinoma and Colorectal Cancer at the 2026 ASCO Meeting https://ml.globenewswire.com/media/de2f6450-22c4-4c16-b785-04cea917de03/small/rgenta-logo-fullcolor-print-1-png.png https://thebostonexaminer.com/article/914161939-amsc-to-report-fourth-quarter-and-fiscal-year-2025-financial-results-on-may-27-2026 The Boston Examiner en PressRelease 2026-05-21T20:45:00+00:00 AMSC to Report Fourth Quarter and Fiscal Year 2025 Financial Results on May 27, 2026 https://ml.globenewswire.com/media/e211940b-e356-45ff-b867-4d8c2353e215/small/unknown-png.png https://thebostonexaminer.com/article/914162044-kadant-authorizes-share-repurchase The Boston Examiner en PressRelease 2026-05-21T20:32:19+00:00 Kadant Authorizes Share Repurchase https://ml.globenewswire.com/media/0ae0f3b1-6350-4b75-a338-ef3bc512c976/small/kadant-logo-blk-jpg.jpg https://thebostonexaminer.com/article/914161982-kadant-declares-cash-dividend The Boston Examiner en PressRelease 2026-05-21T20:31:40+00:00 Kadant Declares Cash Dividend https://ml.globenewswire.com/media/0ae0f3b1-6350-4b75-a338-ef3bc512c976/small/kadant-logo-blk-jpg.jpg https://thebostonexaminer.com/article/914129096-camp4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4 The Boston Examiner en PressRelease 2026-05-21T20:05:00+00:00 CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/72048fc6-0a8d-4ed2-9be8-ec0ee0afd8ba/small/cmp4-21-logo-full-color-jpg.jpg https://thebostonexaminer.com/article/914129173-cue-biopharma-to-present-at-the-2026-jefferies-global-healthcare-conference The Boston Examiner en PressRelease 2026-05-21T20:05:00+00:00 Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference https://ml.globenewswire.com/media/10541379-34cc-4869-a26f-fd99feead42a/small/cue-bio-brand-strategy-graphics-jpg.jpg https://thebostonexaminer.com/article/914130503-beta-bionics-updates-commercialization-timeline-expectations-for-mint-its-patch-pump-in-development The Boston Examiner en PressRelease 2026-05-21T20:04:00+00:00 Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development https://ml.globenewswire.com/media/dd9f136d-aea8-46b4-8bfa-63568d4bc933/medium/mint-by-beta-bionics.jpg https://thebostonexaminer.com/article/914131066-liquidstack-gigamodular-cdu-platform-is-now-commercially-available-with-expanded-14-mw-capacity The Boston Examiner en PressRelease 2026-05-21T20:00:00+00:00 LiquidStack GigaModular™ CDU Platform Is Now Commercially Available with Expanded 14 MW Capacity https://ml.globenewswire.com/media/1dfc94c6-150d-4cd0-ac94-e74309565c15/medium/gigamodular-14mw.jpg